dr. o’malley on the optimal use of parp inhibitors in advanced ovarian cancer
Published 4 years ago • 95 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
1:18
dr. o'malley on the tolerability of parp inhibitors in ovarian cancer
-
1:08
dr. o'malley discusses the current role of parp inhibitors in ovarian cancer
-
1:11
dr. o'malley on toxicity profiles of parp inhibitors in ovarian cancer
-
1:14
dr. o'malley discusses parp combinations in ovarian cancer
-
1:15
dr. o’malley on the safety profile of mirvetuximab in ovarian cancer
-
33:20
ovarian cancer and immunotherapy with dr. dmitriy zamarin
-
58:44
what’s new with parp inhibitors and ovarian cancer?
-
54:35
latest advances in ovarian cancer: what to know
-
2:45
karen lu, md, discusses how parp inhibitors have changed the management of advanced ovarian cancer
-
6:43
sequencing parp inhibitors in advanced ovarian cancer
-
52:36
untreated pid and its long term damage on your sexual and sperm health
-
0:58
dr. o’malley on the utility of mirvetuximab in ovarian cancer
-
1:08
dr. o’malley on the state of immunotherapy in ovarian cancer
-
1:22
dr. penson on the eligibility criteria for parp inhibitors in advanced ovarian cancer
-
1:22
dr. gunderson on the use of parp inhibitors in all-comers with ovarian cancer
-
1:09
dr. o’malley on research with immunotherapy in ovarian cancer
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
-
1:10:07
optimizing the use of parp inhibitors in ovarian cancer
-
9:39
parp inhibitor selection in ovarian cancer
-
1:00
dr. o’malley on the forward ii phase ib study in ovarian cancer
-
1:40
dr. hardesty on bevacizumab/parp inhibitor combination in ovarian cancer
-
4:17
maintenance therapy in ovarian cancer: parp inhibitors